OS Therapies Incorporated — Company profile
Healthcare · Biotechnology · United States
Last price 1.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 57.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company’s pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
Details
| Name | OS Therapies Incorporated |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 5 |
| Founded | 2018 |
| Ipo Date | 2024-08-01 |
| Ceo | Paul Romness |
| Country | United States |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 4.00 |
| Isin | US68764Y2072 |
| Cusip | 68764Y207 |
| Cik | 1795091 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Paul A. Romness M.P.H. | Founder, Chairman, President and Chief Executive Officer |
| Dr. Robert G. Petit II, Ph.D. | Chief Medical Officer and Chief Scientific Officer |
| Francis Knuettel II, M.B.A. | Chief Financial Officer |
| Jack Doll | Chief of Staff |
| Gerald E. Commissiong | Chief Business Officer |
| Kerry M. Clem | Chief Commercial Officer |
Contact
| Address | 115 Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638, United States |
| Phone | 410 297 7793 |
| Website | https://ostherapies.com |